(Q46701051)

24 December 2017

title

Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy (English)

1 reference

24 December 2017

0 references

Rajiv Agarwal

1

1 reference

24 December 2017

publication date

13 September 2005

1 reference

24 December 2017

American Journal of Physiology - Renal Physiology

published in

1 reference

24 December 2017

volume

290

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

F600-5

1 reference

24 December 2017

Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Nontraditional risk factors for cardiovascular disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Antiinflammatory and antiarteriosclerotic effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

The influence of increasing dialysis treatment time and reducing dry weight on blood pressure control in hemodialysis patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Elevated levels of authentic plasma hydroperoxides in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Evolving strategies for renoprotection: diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Peroxisome proliferator-activated receptors and cardiovascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

Role of oxidative stress in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00289.2005

10.1152/AJPRENAL.00289.2005

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16159895

1 reference

24 December 2017